<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920579</url>
  </required_header>
  <id_info>
    <org_study_id>183PK18034</org_study_id>
    <nct_id>NCT03920579</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers</brief_title>
  <official_title>A Sequence-randomized, Open-label, 3-way Crossover, Single Oral Dose Clinical Trial to Investigate the Pharmacokinetic Characteristics and Safety/Tolerability According to Formulations of CKD-386 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      a study to investigate the pharmacokinetic characteristics and safety/tolerability according
      to formulations of CKD-386 in healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A sequence-randomized, open-label, 3-way crossover, single oral dose clinical trial to
      investigate the pharmacokinetic characteristics and safety/tolerability according to
      formulations of CKD-386 in healthy male volunteers
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t of each main component after single dose of CKD-386 formulation 1, CKD-386 formulation 2 or D326, D337, D013</measure>
    <time_frame>0(predose)~72 hour at Day1~Day3, Day15~Day17, Day29~Day31</time_frame>
    <description>AUC0-t: Area under the concentration-time curve from time zero to time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of each main component after single dose of CKD-386 formulation 1, CKD-386 formulation 2 or D326, D337, D013</measure>
    <time_frame>0(predose)~72 hour at Day1~Day3, Day15~Day17, Day29~Day31</time_frame>
    <description>Cmax: Maximum plasma concentration of the drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf each main component or the metabolite of the component after single dose of CKD-386 formulation 1, CKD-386 formulation 2 and D326, D337, D013</measure>
    <time_frame>0(predose)~72 hour at Day1~D3, Day15~D17, Day29~31</time_frame>
    <description>AUCinf: Area under the concentration-time curve from zero up to ∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of each main component or the metabolite of the component after single dose of CKD-386 formulation 1, CKD-386 formulation 2 and D326, D337, D013</measure>
    <time_frame>0(predose)~72 hour at Day1~Day3, Day15~Day17, Day29~Day31</time_frame>
    <description>Tmax: Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of each main component or the metabolite of the component after single dose of CKD-386 formulation 1, CKD-386 formulation 2 and D326, D337, D013</measure>
    <time_frame>0(predose)~72 hour at Day1~Day3, Day15~Day17, Day29~Day31</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of each main component after single dose of CKD-386 formulation 1, CKD-386 formulation 2 and D326, D337, D013</measure>
    <time_frame>0(predose)~72 hour at Day1~Day3, Day15~Day17, Day29~Day31</time_frame>
    <description>CL/F: Apparent total body clearance of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of each main component after single dose of CKD-386 formulation 1, CKD-386 formulation 2 and D326, D337, D013</measure>
    <time_frame>0(predose)~72 hour at Day1~Day3, Day15~Day17, Day29~Day31</time_frame>
    <description>Vd/F: Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of the metabolite of each component after single dose of CKD-386 formulation 1, CKD-386 formulation 2 and D326, D337, D013</measure>
    <time_frame>0(predose)~72 hour at Day1~Day3, Day15~Day17, Day29~Day31</time_frame>
    <description>AUC0-t: Area under the concentration-time curve from time zero to time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of the metabolite of each component after single dose of CKD-386 formulation 1, CKD-386 formulation 2 and D326, D337, D013</measure>
    <time_frame>0(predose)~72 hour at Day1~Day3, Day15~Day17, Day29~Day31</time_frame>
    <description>Cmax: Maximum plasma concentration of the drug</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: D326, D337, D013(3 tabs, once)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 2(1 tab, once)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 1(1 tab, once)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: D326, D337, D013</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D326, D337, D013(3 tabs, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: CKD-386 formulation 2(1 tab, once)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D326, D337, D013 (3 tabs, once)/ Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: CKD-386 formulation 1(1 tab, once)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-386 formulation 1</intervention_name>
    <description>A single oral dose of 1 tablet under fasting conditions for each period</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <other_name>CKD-386 Test 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-386 formulation 2</intervention_name>
    <description>A single oral dose of 1 tablet under fasting conditions for each period</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <other_name>CKD-386 Test 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D326, D337 and D013</intervention_name>
    <description>A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <other_name>CKD-386 Reference</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers aged between ≥20 and ≤45 years old

          2. Weight ≥ 50 kg, with calculated body mass index(BMI) of ≥ 18.5 and ≤ 27.0 kg/m2

          3. Those who have no congenital chronic disease or chronic disease requiring treatment
             and who have no pathological symptoms or findings

          4. Those who are judged to be eligible for clinical trials based on laboratory and ECG
             results during screening tests

          5. Those who voluntarily decide to participate and agree to comply with the cautions
             after hearing and fully understanding the detailed description of this clinical trial

        Exclusion Criteria:

          1. History of presence of hepatobiliary, renal, cardiovascular, endocrine, respiratory,
             gastrointestinal, hematological, neurologic, psychiatric or musculoskeletal disorders
             affecting absorption, distribution, metabolism and excretion of the drug

          2. Genetic problems such as galactose intolerance, Lapp lactose deficiency or
             glucose-galactose malabsorption

          3. Those who are deemed unfit by the investigators to participate in the clinical trial
             for other reasons including the results of laboratory tests
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongseong Shin, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials Center, Gil Medical Center, Incheon, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongseong Shin, M.D, Ph.D</last_name>
    <phone>+82-32-460-9459</phone>
    <email>dsshin@gilhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongseong Shin, M.D, Ph.D</last_name>
      <phone>+82-32-460-9459</phone>
      <email>dsshin@gilhospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-386</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>D326</keyword>
  <keyword>D337</keyword>
  <keyword>D013</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

